Literature DB >> 20084138

Hepatitis B in childhood: An update for the paediatrician.

L T Yeung1, E A Roberts.   

Abstract

Hepatitis B virus (HBV) infection may lead to acute or chronic hepatitis, cirrhosis and hepatocellular carcinoma. The incidence rate of paediatric hepatitis B is 0.2/100,000 to 1.8/100,000 in Canada. Hepatitis B virus infection is acquired largely through mother-to-infant (vertical) or community-based (horizontal) transmission in early childhood, whereas older children are susceptible to HBV infection through exposure to contaminated blood during intravenous drug use or through sexual transmission. Immigrants from endemic areas and some Native Canadian populations are also at a higher risk for HBV infection. Infection with HBV may manifest in three forms: acute self-limited hepatitis, chronic hepatitis or massive hepatic necrosis causing acute liver failure. The identification of HBV infection and the characterization of the disease relies on serological and virological tests. The course of chronic hepatitis B may be classified into three phases: an immunotolerant phase, an active phase and an inactive phase. Current treatment options include interferon-alpha and lamivudine for individuals with elevated serum alanine aminotransferase levels and markers of persistent viral replication. Children with chronic hepatitis B require regular monitoring and age-appropriate lifestyle counselling. Paediatricians are well-positioned to promote vaccination and encourage testing of those who are at risk for hepatitis B. With effective universal vaccination against hepatitis B, this infection could be essentially eliminated in Canada.

Entities:  

Keywords:  Diagnosis; Hepatitis B virus; Natural history; Review; Treatment; Vaccination

Year:  2001        PMID: 20084138      PMCID: PMC2805970          DOI: 10.1093/pch/6.9.655

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  33 in total

1.  Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

Authors:  E M Sokal; H S Conjeevaram; E A Roberts; F Alvarez; E M Bern; P Goyens; P Rosenthal; A Lachaux; M Shelton; J Sarles; J Hoofnagle
Journal:  Gastroenterology       Date:  1998-05       Impact factor: 22.682

2.  Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis.

Authors:  R Iorio; P Pensati; S Botta; S Moschella; N Impagliazzo; P Vajro; A Vegnente
Journal:  Pediatr Infect Dis J       Date:  1997-10       Impact factor: 2.129

3.  Lamivudine as initial treatment for chronic hepatitis B in the United States.

Authors:  J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

4.  Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.

Authors:  Y F Liaw; S L Tsai; R N Chien; C T Yeh; C M Chu
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

5.  Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.

Authors:  H J Schmitt; M Knuf; E Ortiz; R Sänger; M C Uwamwezi; A Kaufhold
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

6.  Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.

Authors:  G V Gregorio; P Jara; L Hierro; C Diaz; A de la Vega; A Vegnente; R Iorio; F Bortolotti; C Crivellaro; L Zancan; H Daniels; B Portmann; G Mieli-Vergani
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

7.  Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana.

Authors:  F E Martinson; K A Weigle; R A Royce; D J Weber; C M Suchindran; S M Lemon
Journal:  Am J Epidemiol       Date:  1998-03-01       Impact factor: 4.897

8.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

9.  Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B.

Authors:  P Vajro; F Migliaro; A Fontanella; G Orso
Journal:  Acta Gastroenterol Belg       Date:  1998 Apr-Jun       Impact factor: 1.316

10.  Treatment of chronic hepatitis B in children with prednisolone withdrawal followed by recombinant interferon alpha.

Authors:  H S Kim; J W Kim; K S Chung
Journal:  Yonsei Med J       Date:  1998-08       Impact factor: 2.759

View more
  3 in total

Review 1.  Viral infections during pregnancy.

Authors:  Michelle Silasi; Ingrid Cardenas; Ja-Young Kwon; Karen Racicot; Paula Aldo; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2015-01-13       Impact factor: 3.886

2.  Prevention of Vertical Transmission of Hepatitis B Within a North Carolina Hospital System.

Authors:  Wesley Sayre; Peyton Thompson
Journal:  Clin Ther       Date:  2021-09-27       Impact factor: 3.393

3.  Global and regional dispersal patterns of hepatitis B virus genotype E from and in Africa: A full-genome molecular analysis.

Authors:  Luicer Anne Olubayo Ingasia; Evangelia Georgia Kostaki; Dimitrios Paraskevis; Anna Kramvis
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.